Related Experiment Video

Updated: Jul 17, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.1K

The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for

Martina Benešová-Schäfer1, Uwe Haberkorn2, John W Babich3

  • 1Translational Radiotheranostics Research Group, German Cancer Research Center, Heidelberg, Germany.

European Urology
|January 15, 2026
PubMed

Insights

Prostate-specific membrane antigen (PSMA) targeted therapies have advanced significantly for prostate cancer. Continued innovation is crucial due to tumor heterogeneity and treatment resistance in metastatic disease.

Area of Science:

  • Oncology
  • Molecular Imaging
  • Radiopharmaceuticals

Background:

  • Prostate-specific membrane antigen (PSMA) is a key target in prostate cancer.
  • PSMA-targeting agents have evolved from diagnostic tools to therapeutics.
  • Metastatic prostate cancer presents challenges due to biological heterogeneity and resistance.

Purpose of the Study:

  • To review the evolution of PSMA-targeting strategies in prostate cancer.
  • To highlight the current role of PSMA in metastatic disease.
  • To emphasize the need for ongoing innovation and combination therapies.

Main Methods:

  • Literature review of PSMA-targeting agents.
  • Analysis of diagnostic and therapeutic applications.
  • Discussion of challenges and future directions.

Main Results:

  • PSMA-targeting strategies have shown significant advancements.
  • PSMA remains a critical biomarker in metastatic prostate cancer.
  • Heterogeneity and resistance necessitate novel approaches.

Conclusions:

  • PSMA-targeting agents are vital in prostate cancer management.
  • Further research into combination strategies is essential.
  • Innovation is key to overcoming treatment resistance.

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...